Unknown

Dataset Information

0

Regulation of Transforming Growth Factor ?-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6.


ABSTRACT: Transforming growth factor ?-activated kinase 1 (TAK1) is a key MAPKKK family protein in interleukin-1? (IL-1?), tumor necrosis factor (TNF), and Toll-like receptor signaling. This study was undertaken to examine the posttranslational modification of TAK1 and its therapeutic regulation in rheumatoid arthritis (RA).The effect of TAK1, IL-1 receptor-associated kinase 1 (IRAK-1), and TNF receptor-associated factor 6 (TRAF6) inhibition was evaluated in IL-1?-stimulated human RA synovial fibroblasts (RASFs). Western blotting, immunoprecipitation, and 20S proteasome assay were used to study the ubiquitination process in RASFs. The efficacy of epigallocatechin-3-gallate (EGCG), a potent antiinflammatory molecule, in regulating these processes in RASFs was evaluated. Molecular docking was performed to examine the interaction of EGCG with human TAK1, IRAK-1, and TRAF6. These findings were confirmed using a rat model of adjuvant-induced arthritis (AIA).Inhibition of TAK1, but not IRAK-1 or TRAF6, completely abrogated IL-1?-induced IL-6 and IL-8 synthesis in RASFs. EGCG inhibited TAK1 phosphorylation at Thr(184/187) and occupied the C(174) position, an ATP-binding site, to inhibit its kinase activity. EGCG pretreatment also inhibited K(63) -linked autoubiquitination of TRAF6, a posttranslational modification essential for TAK1 autophosphorylation, by forming a stable H bond at the K(124) position on TRAF6. Furthermore, EGCG enhanced proteasome-associated deubiquitinase expression to rescue proteins from proteasomal degradation. Western blot analyses of joint homogenates from rats with AIA showed a significant increase in K(48) -linked polyubiquitination, TAK1 phosphorylation, and TRAF6 expression when compared to naive rats. Administration of EGCG (50 mg/kg/day) for 10 days ameliorated AIA in rats by reducing TAK1 phosphorylation and K(48) -linked polyubiquitination.Our findings provide a rationale for targeting TAK1 for the treatment of RA with EGCG.

SUBMITTER: Singh AK 

PROVIDER: S-EPMC5383419 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6.

Singh Anil K AK   Umar Sadiq S   Riegsecker Sharayah S   Chourasia Mukesh M   Ahmed Salahuddin S  

Arthritis & rheumatology (Hoboken, N.J.) 20160201 2


<h4>Objective</h4>Transforming growth factor β-activated kinase 1 (TAK1) is a key MAPKKK family protein in interleukin-1β (IL-1β), tumor necrosis factor (TNF), and Toll-like receptor signaling. This study was undertaken to examine the posttranslational modification of TAK1 and its therapeutic regulation in rheumatoid arthritis (RA).<h4>Methods</h4>The effect of TAK1, IL-1 receptor-associated kinase 1 (IRAK-1), and TNF receptor-associated factor 6 (TRAF6) inhibition was evaluated in IL-1β-stimula  ...[more]

Similar Datasets

| S-EPMC2206335 | biostudies-literature
| S-EPMC3618592 | biostudies-literature
| S-EPMC4002512 | biostudies-literature
| S-EPMC1753134 | biostudies-literature
2024-07-17 | GSE208144 | GEO
| S-EPMC7919303 | biostudies-literature
| S-EPMC10894125 | biostudies-literature
| S-EPMC4344457 | biostudies-literature
| S-EPMC10307631 | biostudies-literature
| S-EPMC102332 | biostudies-literature